RPG Life Sciences Limited
NSE: RPGLIFE BSE: RPGLIFE
Prev Close
1978.9
Open Price
2025
Volume
5,675
Today Low / High
1953.9 / 2030
52 WK Low / High
1835 / 2725
Range
1,900 - 2,100
Prev Close
1977.7
Open Price
1994
Volume
153
Today Low / High
1961.4 / 1997.75
52 WK Low / High
1772.05 / 2715.9
Range
1,886 - 2,084
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2000 (target range: 1,900 - 2,100), reflecting a change of 21.1 (1.06625%). On the BSE, it is listed at 1985.2 (target range: 1,886 - 2,084), showing a change of 7.5 (0.37923%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
RPG Life Sciences Limited Graph
RPG Life Sciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for RPG Life Sciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,000.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,985.20 | 2,005.05 | 1,804.55 - 2,205.56 |
| 2,024.90 | 1,619.92 - 2,429.88 | ||
| 2,044.76 | 1,431.33 - 2,658.18 | ||
| Bearish Scenario | 1,985.20 | 1,965.35 | 1,768.81 - 2,161.88 |
| 1,945.50 | 1,556.40 - 2,334.60 | ||
| 1,925.64 | 1,347.95 - 2,503.34 |
Overview of RPG Life Sciences Limited
ISIN
INE105J01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
11,067
Market Cap
32,919,255,456
Last Dividend
20
Official Website
IPO Date
2002-08-12
DCF Diff
-4,161.83
DCF
6,513
Financial Ratios Every Investor Needs
Stock Dividend of RPGLIFE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-06-27 | June 27, 25 | 20 | 20 | 2025-06-27 | 2025-08-15 | |
| 2024-06-28 | June 28, 24 | 16 | 16 | 2024-06-28 | 2024-08-15 | |
| 2023-07-21 | July 21, 23 | 12 | 12 | 2023-07-21 | 2023-09-03 | |
| 2022-07-14 | July 14, 22 | 9.6 | 9.6 | 2022-07-15 | 2022-08-28 | |
| 2021-08-13 | August 13, 21 | 7.2 | 7.2 | 2021-08-17 | 2021-09-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 653.43 Cr | 214.01 Cr | 439.42 Cr | 0.6725 | 1.47 Cr | 127.21 Cr | 313.28 Cr | 183.24 Cr | 110.80 | 159.65 Cr | 0.2804 |
| 2024-03-31 | 577.48 Cr | 371.29 Cr | 392.78 Cr | 0.6802 | 9.36 Cr | 132.89 Cr | 109.99 Cr | 87.66 Cr | 53.00 | 136.35 Cr | 0.1518 |
| 2023-03-31 | 509.08 Cr | 340.59 Cr | 169.69 Cr | 0.3333 | 8.93 Cr | 117.75 Cr | 87.47 Cr | 67.64 Cr | 40.90 | 108.33 Cr | 0.1329 |
| 2022-03-31 | 437.16 Cr | 150.21 Cr | 286.95 Cr | 0.6564 | 8.97 Cr | 100.63 Cr | 70.74 Cr | 51.48 Cr | 31.13 | 90.24 Cr | 0.1178 |
| 2021-03-31 | 383.40 Cr | 137.64 Cr | 245.76 Cr | 0.6410 | 8.88 Cr | 95.36 Cr | 54.72 Cr | 40.00 Cr | 24.19 | 71.84 Cr | 0.1043 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 28.70 Cr | 657.81 Cr | 127.28 Cr | 530.5300 Cr | 0.00 Cr | -139.61 Cr | 92.98 Cr | 165.13 Cr | 0.00 Cr | 0.00 Cr | 1.18 Cr | 119.8300 Cr |
| 2024-03-31 | 19.72 Cr | 512.87 Cr | 138.02 Cr | 374.8500 Cr | 0.00 Cr | -19.72 Cr | 101.00 Cr | 181.81 Cr | 1.84 Cr | 0.00 Cr | 1.20 Cr | 130.9600 Cr |
| 2023-03-31 | 24.82 Cr | 419.35 Cr | 111.75 Cr | 307.6000 Cr | 0.01 Cr | -24.81 Cr | 95.05 Cr | 116.30 Cr | 31.88 Cr | 3.02 Cr | 0.18 Cr | 102.7800 Cr |
| 2022-03-31 | 56.94 Cr | 344.61 Cr | 88.84 Cr | 255.7700 Cr | 0.94 Cr | -56.00 Cr | 82.99 Cr | 100.09 Cr | 2.46 Cr | 3.13 Cr | -12.48 Cr | 80.1100 Cr |
| 2021-03-31 | 40.36 Cr | 303.39 Cr | 86.94 Cr | 216.4500 Cr | 2.02 Cr | -38.34 Cr | 58.33 Cr | 87.94 Cr | 24.53 Cr | 0.00 Cr | -1.25 Cr | 79.6900 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 77.8600 Cr | -41.8000 Cr | -27.0800 Cr | 41.8300 Cr | 8.9800 Cr | 28.7000 Cr | -36.0300 Cr | 183.2400 Cr | 0.0000 Cr | -26.4600 Cr | 6.1900 Cr |
| 2024-03-31 | 94.3600 Cr | -79.1500 Cr | -20.3100 Cr | 25.1300 Cr | -5.1000 Cr | 19.7200 Cr | -69.2300 Cr | 87.6600 Cr | -0.0100 Cr | -19.8500 Cr | -5.9500 Cr |
| 2023-03-31 | 90.8200 Cr | -105.8100 Cr | -17.1200 Cr | 58.0900 Cr | -32.1200 Cr | 24.8200 Cr | -32.7300 Cr | 91.6800 Cr | -0.2800 Cr | -15.8800 Cr | -12.0600 Cr |
| 2022-03-31 | 64.7500 Cr | -34.6600 Cr | -13.5100 Cr | 40.8000 Cr | 16.5800 Cr | 56.9400 Cr | -23.9500 Cr | 73.1700 Cr | -0.4200 Cr | -11.9100 Cr | -24.6600 Cr |
| 2021-03-31 | 58.2700 Cr | -7.9600 Cr | -10.4900 Cr | 49.7600 Cr | 39.8200 Cr | 40.3600 Cr | -8.5100 Cr | 53.5800 Cr | -9.0700 Cr | 0.0000 Cr | -11.7200 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 180.03 Cr | 105.60 Cr | 74.43 Cr | 0.4134 | 34.38 Cr | 22.13 Cr | 13.38 | 34.50 Cr | 0.1229 |
| 2025-09-30 | 181.68 Cr | 107.96 Cr | 73.72 Cr | 0.4058 | 33.81 Cr | 36.85 Cr | 22.28 | 54.79 Cr | 0.2028 |
| 2025-06-30 | 168.92 Cr | 60.02 Cr | 108.90 Cr | 0.6447 | 30.33 Cr | 26.29 Cr | 15.90 | 40.70 Cr | 0.1556 |
| 2025-03-31 | 143.09 Cr | 48.72 Cr | 94.37 Cr | 0.6595 | 62.77 Cr | 117.35 Cr | 70.96 | 25.48 Cr | 0.8201 |
| 2024-12-31 | 172.71 Cr | 56.11 Cr | 116.60 Cr | 0.6751 | 43.70 Cr | 34.93 Cr | 21.12 | 52.47 Cr | 0.2022 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 131.80 Cr | 91.72 Cr | 223.52 Cr | 118.78 Cr | 106.97 Cr | 487.90 Cr | 186.28 Cr | 705.71 Cr | 151.76 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 264.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -530.53 Cr |
| 2025-03-31 | 28.70 Cr | 235.90 Cr | 265.51 Cr | 86.76 Cr | 92.98 Cr | 465.25 Cr | 165.13 Cr | 657.81 Cr | 127.28 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 125.94 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -379.38 Cr |
| 2024-09-30 | 34.03 Cr | 91.91 Cr | 125.94 Cr | 86.41 Cr | 99.16 Cr | 330.17 Cr | 181.79 Cr | 554.37 Cr | 174.99 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 26.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 117.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 34.93 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 4.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 26.76 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,697.80 | ₹4,073,590,912,066.00 | ₹3,930,868.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,290.00 | ₹1,669,797,368,200.00 | ₹244,814.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,033.60 | ₹1,365,153,526,784.00 | ₹240,277.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,231.80 | ₹1,025,557,496,442.00 | ₹761,638.00 |
| Lupin Limited | LUPIN | ₹2,190.80 | ₹1,000,755,249,200.00 | ₹367,005.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹906.80 | ₹912,452,982,132.00 | ₹347,388.00 |
| Mankind Pharma Limited | MANKIND | ₹2,159.30 | ₹891,369,991,970.00 | ₹116,092.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,236.30 | ₹718,045,046,515.00 | ₹1,217,552.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,698.00 | ₹681,281,370,000.00 | ₹69,308.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,979.40 | ₹558,588,281,335.00 | ₹233,253.00 |
| Laurus Labs Limited | LAURUSLABS | ₹980.35 | ₹529,248,400,164.00 | ₹951,956.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,443.40 | ₹366,196,668,261.00 | ₹54,740.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,837.00 | ₹354,442,365,288.00 | ₹25,237.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,894.10 | ₹303,879,933,500.00 | ₹86,928.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,503.70 | ₹285,060,228,398.00 | ₹62,288.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,349.00 | ₹219,201,935,981.00 | ₹408,785.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,649.50 | ₹216,237,500,000.00 | ₹2,110.00 |
| Eris Lifesciences Limited | ERIS | ₹1,428.20 | ₹194,544,963,726.00 | ₹13,251.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,435.00 | ₹172,369,558,715.00 | ₹18,003.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹988.90 | ₹156,611,843,797.00 | ₹50,041.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹793.40 | ₹155,953,182,582.00 | ₹14,005.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹853.00 | ₹152,780,719,110.00 | ₹355,318.00 |
| Cohance Lifesciences Limited | COHANCE | ₹386.60 | ₹147,900,456,324.00 | ₹145,589.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,836.00 | ₹139,557,473,856.00 | ₹30,496.00 |
| Granules India Limited | GRANULES | ₹569.30 | ₹138,151,300,019.00 | ₹257,455.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹955.05 | ₹117,219,016,800.00 | ₹36,675.00 |
| Viyash Scientific Limited | VIYASH | ₹216.91 | ₹94,617,347,803.00 | ₹984,027.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,288.50 | ₹87,785,831,707.00 | ₹10,667.00 |
| Strides Pharma Science Limited | STAR | ₹863.10 | ₹79,554,269,453.00 | ₹148,496.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹789.55 | ₹71,570,570,978.00 | ₹68,670.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹452.50 | ₹69,278,681,245.00 | ₹71,811.00 |
| FDC Limited | FDC | ₹381.20 | ₹62,063,204,021.00 | ₹23,733.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹299.85 | ₹58,645,207,528.00 | ₹235,068.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹144.94 | ₹47,036,158,965.00 | ₹2,957,569.00 |
| Innova Captab Limited | INNOVACAP | ₹723.15 | ₹41,382,207,406.00 | ₹38,298.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹399.00 | ₹36,416,730,000.00 | ₹111,236.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹326.40 | ₹35,566,262,496.00 | ₹17,410.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹685.00 | ₹34,742,586,925.00 | ₹32,360.00 |
| Suven Life Sciences Limited | SUVEN | ₹146.50 | ₹33,324,941,000.00 | ₹213,933.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,995.00 | ₹32,995,334,925.00 | ₹5,638.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹306.35 | ₹30,721,545,713.00 | ₹21,387.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹397.75 | ₹28,003,887,063.00 | ₹27,679.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: female
Year Born:
FAQs about RPG Life Sciences Limited
The CEO is Ashok Nair.
The current price is ₹1,990.40.
The range is ₹1835-2725.
The market capitalization is ₹3,291.93 crores.
The dividend yield is 1.00%.
The P/E ratio is 16.25.
The company operates in the Healthcare sector.
Overview of RPG Life Sciences Limited (ISIN: INE105J01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,291.93 crores and an average daily volume of 11,067 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹20.